No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > PARP Inhibitor Therapy

Toggle Menu

PARP Inhibitor Therapy

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

PARP inhibitors for pancreatic cancer

Olaparib (Lynparza) is FDA approved for maintenance treatment of pancreatic cancer in people with a BRCA1 or BRCA2 mutation whose disease has not progressed after completing first-line platinum-based chemotherapy.

Clinical trials are looking at whether people with pancreatic cancer who have a different inherited gene mutation, such as PALB2 or ATM will also have a response to a PARP inhibitor

You can find research studies enrolling patients with inherited pancreatic cancer by visiting FORCE's Research Search and Match Tool.

Updated 12/31/2019

FORCE:Facing Our Risk of Cancer Empowered